Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, released updated Phase 2 HARMONIC trial data demonstrating that LP-300, in combination with carboplatin and pemetrexed, provided a progression-free survival (PFS) benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who had progressed following tyrosine kinase inhibitor (TKI) therapy. The emerging data showed a median PFS of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort. The company highlighted an exceptionally clean safety and tolerability profile, supporting a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles.
These findings are significant for the NSCLC treatment landscape, particularly for the L858R mutation subtype, which represents a substantial proportion of EGFR-mutant cases. Patients who progress on TKI therapy have limited options, and the data suggest LP-300 could offer a meaningful benefit with manageable toxicity. The extension to eight cycles may allow for sustained disease control, potentially improving outcomes for this difficult-to-treat population.
Lantern Pharma leverages its proprietary RADR platform, an AI and machine learning system, to streamline oncology drug development. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300, which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern has commercially launched withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription-based research tool for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The updated HARMONIC trial data underscore the potential of AI-driven precision oncology to identify patient subgroups most likely to benefit from targeted therapies. For the industry, this approach could reduce trial costs and accelerate development timelines. For patients with EGFR L858R-mutant NSCLC, the findings offer hope for improved outcomes with a well-tolerated regimen. The FDA's clearance to extend dosing further validates the safety profile and may enhance therapeutic efficacy.
Full details are available in the press release at https://ibn.fm/uaAUc. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
